Literature DB >> 9797213

A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.

A A Firsov1, S N Vostrov, A A Shevchenko, Y A Portnoy, S H Zinner.   

Abstract

Time-kill studies, even those performed with in vitro dynamic models, often do not provide definitive comparisons of different antimicrobial agents. Also, they do not allow determinations of equiefficient doses or predictions of area under the concentration-time curve (AUC)/MIC breakpoints that might be related to antimicrobial effects (AMEs). In the present study, a wide range of single doses of trovafloxacin (TR) and twice-daily doses of ciprofloxacin (CI) were mimicked in an in vitro dynamic model. The AMEs of TR and CI against gram-negative bacteria with similar susceptibilities to both drugs were related to AUC/MICs that varied over similar eight-fold ranges [from 54 to 432 and from 59 to 473 (microg . h/ml)/(microg/ml), respectively]. The observation periods were designed to include complete bacterial regrowth, and the AME was expressed by its intensity (the area between the control growth in the absence of antibiotics and the antibiotic-induced time-kill and regrowth curves up to the point where viable counts of regrowing bacteria equal those achieved in the absence of drug [IE]). In each experiment monoexponential pharmacokinetic profiles of TR and CI were simulated with half-lives of 9.2 and 4.0 h, respectively. Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml). The slopes and intercepts of these relationships differed for TR and CI, and the IE-log AUC/MIC plots were not superimposed, although they were similar for all bacteria with a given antibiotic. By using the relationships between IE and log AUC/MIC, TR was more efficient than CI. The predicted value of the AUC/MIC breakpoint for TR [mean for all three bacteria, 63 (microg . h/ml)/(microg/ml)] was approximately twofold lower than that for CI. Based on the IE-log AUC/MIC relationships, the respective dose (D)-response relationships were reconstructed. Like the IE-log AUC/MIC relationships, the IE-log D plots showed TR to be more efficient than CI. Single doses of TR that are as efficient as two 500-mg doses of CI (500 mg given every 12 h) were similar for the three strains (199, 226, and 203 mg). This study suggests that in vitro evaluation of the relationships between IE and AUC/MIC or D might be a reliable basis for comparing different fluoroquinolones and that the results of such comparative studies may be highly dependent on their experimental design and datum quantitation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797213      PMCID: PMC105953     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model.

Authors:  B Wiedemann; A Jansen
Journal:  J Antimicrob Chemother       Date:  1990-07       Impact factor: 5.790

2.  Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model.

Authors:  A A Firsov; V M Chernykh; S M Navashin
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

4.  The comparative pharmacokinetics of five quinolones.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

5.  Influence of ampicillin elimination half-life on in-vitro bactericidal effect.

Authors:  C A White; R D Toothaker
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

Review 6.  In vitro models for the study of antibiotic activities.

Authors:  J Blaser; S H Zinner
Journal:  Prog Drug Res       Date:  1987

7.  Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.

Authors:  A A Firsov; A A Shevchenko; S N Vostrov; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  Pharmacokinetic considerations in quinolone therapy.

Authors:  C H Nightingale
Journal:  Pharmacotherapy       Date:  1993 Mar-Apr       Impact factor: 4.705

9.  In vitro simulated pharmacokinetics profiles: forecasting antibiotic optimal dosage.

Authors:  A A Firsov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991       Impact factor: 2.441

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  9 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Use of Modeling Techniques to Aid in Antibiotic Selection.

Authors:  Alexander A. Firsov; Stephen H. Zinner
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

3.  Pharmacodynamics, a tool for a better use of antibiotics?

Authors:  F Crokaert
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

Review 4.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

5.  Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; M T ten Kate; L Guo; P Working; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.

Authors:  S N Vostrov; O V Kononenko; I Y Lubenko; S H Zinner; A A Firsov
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.

Authors:  Alexander A Firsov; Irene Y Lubenko; Sergey N Vostrov; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model.

Authors:  Parth N Shah; Kush N Shah; Justin A Smolen; Jasur A Tagaev; Jose Torrealba; Lan Zhou; Shiyi Zhang; Fuwu Zhang; Patrick O Wagers; Matthew J Panzner; Wiley J Youngs; Karen L Wooley; Carolyn L Cannon
Journal:  Sci Rep       Date:  2018-04-23       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.